Baseline characteristics of the participants at inclusion.
Neurological and gastrointestinal symptoms, headache, nausea, vomiting
ADVERSE EVENTS
Data are number with percentage or median with IQRs. INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PYR, pyrimethamine.*Other HIV-1 subtypes include CRF01-AE (†NNRTIs were rilpivirine (‡INSTIs were dolutegravir (During the 6-week study duration after inclusion, a total of 103 adverse events (AEs) were reported by the trial participants (tables S1 and S2). Except for three grade 3 AE (two with pyrimethamine alone and one in the combination arm), all were of grade 2 or lower severity (table S3). Most AEs (84 of 103) were experienced on pyrimethamine at a comparable rate between the monotherapy and the combination arms. Neurological and gastrointestinal symptoms were the most common AE categories across all interventional arms, with nausea, vomiting, and headache being the most frequently reported. No serious AEs (SAEs) were observed during the trial, and all AEs were resolved after the intervention. No AIDS-defining illnesses occurred during or after the study. The blood CD4